The Gynecologic Oncology Group (GOG) is a multicenter clinical research organization to improve the treatment of patients with gynecologic malignancies. A multidisciplinary approach to treatment has been developed in the subspecialty of gynecologic oncology, utilizing all available therapy modalities including radical surgery, radiation therapy, chemotherapy and immunotherapy. The University of Miami School of Medicine has been among the most active participants in this development since its early beginning in 1965. The GOG was first formed (1970) and the University of Miami became a member in 1972. Until 1979 we had research commitments and funds through conflicting other grants and did not pursue funding in the GOG. Since then, we started again to actively participate in the GOG and became full members in February 1983. The detailed objectives, goals and progress of the GOG have been stated in the renewal grant. We fully endorse those objectives and goals. In the last year we have entered 94 patients into GOG protocols. Until now, all our patients were treated at Jackson Memorial Hospital as our only institution, but now we are expanding to an affiliated hospital (Mt. Sinai Medical Center), further increasing the number of patients eligible for study entry. It is anticipated that with funding over 150 patients will be entered on protocol studies per year. The gynecologic oncologists, radiation therapists, medical oncologists and pathologists are committed to participate in all GOG activities: placing patients on active protocols, providing follow-up data, attending group meetings and getting involved in the development of new protocols and pilot studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA037234-04
Application #
3557972
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1984-07-01
Project End
1989-06-30
Budget Start
1987-05-01
Budget End
1989-06-30
Support Year
4
Fiscal Year
1987
Total Cost
Indirect Cost
Name
University of Miami School of Medicine
Department
Type
Schools of Medicine
DUNS #
City
Miami
State
FL
Country
United States
Zip Code
33101
Tate Thigpen, J; Blessing, John A; DeGeest, Koen et al. (2004) Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group study. Gynecol Oncol 93:336-9
Thigpen, J Tate; Blessing, John A; Olt, George et al. (2003) Cisplatin as second-line therapy in ovarian carcinoma treated initially with single-agent paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol 90:581-6
Keys, Henry M; Bundy, Brian N; Stehman, Frederick B et al. (2003) Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecol Oncol 89:343-53
Spirtos, Nick M; Westby, Cynthia M; Averette, Hervy E et al. (2002) Blood transfusion and the risk of recurrence in squamous cell carcinoma of the cervix: a gynecologic oncology group study. Am J Clin Oncol 25:398-403
Feun, L G; Blessing, J A; Barrett, R J et al. (1993) A phase II trial of tricyclic nucleoside phosphate in patients with advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Study. Am J Clin Oncol 16:506-8
Berenberg, J L; Tangen, C; Macdonald, J S et al. (1993) VM-26 in gastric cancer. A Southwest Oncology Group study. Invest New Drugs 11:333-4
Asbury, R F; Blessing, J A; McGuire, W P et al. (1990) Aminothiadiazole (NSC 4728) in patients with advanced carcinoma of the endometrium. A phase II study of the Gynecologic Oncology group. Am J Clin Oncol 13:39-41
Roberts, J A; Blessing, J A; McGehee, R et al. (1987) Phase II trial of dichloromethotrexate in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Cancer Treat Rep 71:1295-6
Muss, H B; Bundy, B N; Homesley, H D et al. (1987) Mitoxantrone in the treatment of advanced non-squamous carcinoma of the cervix (a phase II trial of the gynecologic oncology group). Invest New Drugs 5:199-202